Metformin derivatives, their preparation methods, and applications
The metformin derivative obtained through molecular modification combines nicotinic acid ribose and metformin. The preparation method involves reacting in a specific solvent and treating with a catalyst and a strongly alkaline aqueous solution to form compound 3. This overcomes the limitations of existing metformin in lipid regulation and reversing cell senescence, and significantly improves lipid metabolism in liver cells and senescence in adipocytes.
Patent Information
- Application Number
- CN202611105271.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-23
- Publication Date
- 2026-11-17
AI Technical Summary
Metformin currently has limited effectiveness in regulating lipids and reversing cellular senescence, and it is difficult to effectively improve lipid metabolism in liver cells and senescence in adipocytes.
The metformin derivative obtained through molecular modification combines nicotinic acid ribose and metformin. The preparation method involves reacting in a specific solvent and treating with a catalyst and a strongly alkaline aqueous solution to form compound 3 with a specific structure.
It significantly reduces triglyceride levels in liver cells, alleviates lipid accumulation, and improves lipid metabolism in liver cells, achieving a dual therapeutic effect on metabolic fatty liver and related tissue damage.
Smart Images

Figure CN123106797A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of drug synthesis technology, specifically to a metformin derivative, its preparation method, and its application. Background Technology
[0002] In recent years, metformin has become one of the most widely used oral hypoglycemic agents for diabetes in clinical practice. Its core mechanism lies in activating the cytochrome AMP-activated protein kinase (AMPK) pathway. In addition to lowering blood sugar, it can also improve insulin resistance, reduce weight, and protect cardiovascular function. However, with the deepening of clinical application, the clinical limitations of traditional metformin have gradually become apparent: (1) Although metformin has lipid-regulating and lipid-inhibiting effects, its lipid-lowering effect is limited when used alone; (2) Although metformin can delay the aging process, its ability to reverse the cellular senescence phenotype and related molecular markers that have already been formed is still relatively limited.
[0003] To address the aforementioned issues, this application explores the molecular structure modification of metformin, aiming to obtain new compounds through molecular modification that can significantly improve lipid metabolism in liver cells while maintaining the level of inhibition of cellular senescence. Summary of the Invention
[0004] Therefore, it is necessary to provide a metformin derivative that can solve the above problems, as well as its preparation method and application.
[0005] A metformin derivative, wherein the metformin derivative is compound 3 having the following structural formula: ; Where X is F, Cl, Br or I.
[0006] A method for preparing the above-mentioned metformin derivative includes the following steps: Step 1: Compound 1, nicotinic acid metformin, and a protecting agent are dissolved in a first organic solvent. The resulting first reaction solution is stirred at 60 ℃~80 ℃. After the reaction is complete, a catalyst is added, and the resulting second reaction solution is stirred at 60 ℃~80 ℃. After the reaction is complete, compound 2 is obtained by separation. The reaction formula is as follows: , Where X is F, Cl, Br or I; Step 2: Dissolve compound 2 in a second organic solvent, add a strongly alkaline aqueous solution at 0-5 °C, and stir the resulting third reaction solution. After the reaction is complete, separate to obtain compound 3, which is the desired metformin derivative. The reaction formula is as follows: .
[0007] In one embodiment, in step one, the molar ratio of nicotinic acid metformin to compound 1 is 1~3:1, the molar ratio of the protective agent to nicotinic acid metformin is 4~8:1, and the molar ratio of the catalyst to compound 1 is 1~3:1.
[0008] In one embodiment, the catalyst is trimethylsilyl trifluoromethanesulfonate; The protective agent is N,O -Bis(trimethylsilyl)acetamide; The catalyst is added by dropping, and the dropping rate is 5 mL / min to 10 mL / min.
[0009] In one embodiment, the first organic solvent is acetonitrile; The mass-to-volume ratio of compound 1 to the first organic solvent is 1 g: 5 mL to 20 mL.
[0010] In one embodiment, in step one, the operation of separating compound 2 after the reaction is completed is as follows: the second reaction solution after the reaction is completed is first neutralized to neutral with saturated sodium bicarbonate, concentrated under reduced pressure to remove the first organic solvent, filtered to obtain an aqueous solution of crude product, and the aqueous solution of crude product is purified by C-18 column chromatography to obtain compound 2, wherein the eluent of the C-18 column chromatography purification is a mixture of acetonitrile and 0.1 wt% hydrochloric acid, and the volume percentage of acetonitrile in the eluent is 10%~30%.
[0011] In one embodiment, in step two, the strongly alkaline aqueous solution is an aqueous solution of sodium hydroxide or potassium hydroxide. The concentration of the strongly alkaline aqueous solution is 0.5M~2M; The molar ratio of the solute in compound 2 to the strongly alkaline aqueous solution is 1:1.5~5.
[0012] In one embodiment, the second organic solvent is methanol; The mass-to-volume ratio of compound 2 to the second organic solvent is 1 g : 2 mL to 6 mL; The strongly alkaline aqueous solution is added dropwise at a rate of 5 mL / min to 20 mL / min.
[0013] In one embodiment, in step two, the operation of separating compound 3 after the reaction is completed is as follows: after the reaction is completed, the third reaction solution is added with hydrochloric acid aqueous solution under ice bath until the pH of the system is less than 7, and concentrated under reduced pressure to obtain crude product. The crude product is purified by reversed-phase column chromatography to obtain compound 3. The eluent for the reversed-phase column chromatography purification is a mixture of acetonitrile and 0.1 wt% hydrochloric acid, and the volume percentage of acetonitrile in the eluent is 5%~20%.
[0014] Application of one of the above-mentioned metformin derivatives in improving lipid metabolism in liver cells and improving adipocyte senescence.
[0015] This invention discloses for the first time a metformin derivative (compound 3) having the above-mentioned structural formula. In conjunction with specific embodiments, the metformin derivative obtained through molecular modification can significantly enhance the reversal effect on hepatocyte lipid deposition (Steatosis) and triglycerides while maintaining the level of inhibiting adipocyte senescence, thereby improving hepatocyte lipid metabolism and ultimately achieving a "dual therapeutic effect" on metabolic fatty liver and related tissue damage. Attached Figure Description
[0016] Figure 1 This is a flowchart illustrating a method for preparing a metformin derivative according to one embodiment.
[0017] Figure 2 It is compound 2' prepared in Example 1. 1 H NMR spectrum.
[0018] Figure 3 It is compound 2' prepared in Example 1. 13 C NMR spectrum.
[0019] Figure 4 This is the HPLC purity chromatogram of compound 3' prepared in Example 2.
[0020] Figure 5 It is compound 3' prepared in Example 2. 1 H NMR spectrum.
[0021] Figure 6 It is compound 3' prepared in Example 2. 13 C NMR spectrum.
[0022] Figure 7 This is the mass spectrum of compound 3' prepared in Example 2.
[0023] Figure 8 The image shows the improvement effect of different drug administration groups on cell senescence under a polarized light microscope in Example 6.
[0024] Figure 9 This is a comparison chart of the effects of different drug administration groups on improving cell senescence in Example 6.
[0025] Figure 10 This is a comparison chart of the improvement effects of different drug administration groups on triglyceride content in Example 7.
[0026] Figure 11 The image shows the improvement effect of different drug administration groups on lipid deposition under a polarized light microscope in Example 7.
[0027] Figure 12 This is a comparison chart of the improvement effects of different drug administration groups on lipid deposition in Example 7. Detailed Implementation
[0028] To make the objectives, technical solutions, and advantages of the present invention clearer, the embodiments of the present invention will be further described below with reference to the accompanying drawings.
[0029] This invention discloses a metformin derivative according to one embodiment, wherein the metformin derivative is compound 3 having the following structural formula: .
[0030] Where X is F, Cl, Br or I.
[0031] Based on the above structural formula, this metformin derivative is a combination of nicotinic acid riboside (NAR) and metformin, and can be simply referred to as NAR metformin.
[0032] This invention discloses for the first time a metformin derivative (compound 3) having the above-mentioned structural formula. In conjunction with specific embodiments, the metformin derivative obtained through molecular modification can significantly reduce the triglyceride level of liver cells and alleviate lipid accumulation in liver cells while maintaining the inhibition of adipocyte senescence, thereby improving lipid metabolism in liver cells and achieving a "dual therapeutic effect" on metabolic fatty liver and related tissue damage.
[0033] In a particular embodiment, X is Cl, and in this case, NAR metformin is compound 3' having the following structural formula: .
[0034] Combination Figure 1 The present invention also discloses a method for preparing the above-mentioned metformin derivative, comprising the following steps: S10. Compound 1, nicotinic acid metformin and a protective agent are dissolved in a first organic solvent. The resulting first reaction solution is stirred at 60 ℃ to 80 ℃. After the reaction is completed, a catalyst is added. The resulting second reaction solution is stirred at 60 ℃ to 80 ℃. After the reaction is completed, compound 2 is separated.
[0035] In S10, the reaction formula is as follows: , Where X is F, Cl, Br or I.
[0036] It should be noted that compound 1 is tetraacetylribose. In this embodiment, nicotinic acid metformin was synthesized in the laboratory, as detailed in patent CN202510664511.1.
[0037] In other embodiments, nicotinic acid metformin may also be commercially available.
[0038] Preferably, in S10, the molar ratio of nicotinic acid metformin to compound 1 is 1~3:1, the molar ratio of the protective agent to nicotinic acid metformin is 4~8:1, and the molar ratio of the catalyst to compound 1 is 1~3:1.
[0039] Preferably, in S10, the catalyst is trimethylsilyl trifluoromethanesulfonate (TMSOTf).
[0040] Preferably, in S10, the protective agent is N,O - Bis(trimethylsilyl)acetamide (BSA).
[0041] Preferably, in S10, the reaction time of the first reaction solution being stirred at 60 ℃ to 80 ℃ is 1 h to 4 h; the reaction time of the second reaction solution being stirred at 60 ℃ to 80 ℃ is 1 h to 4 h.
[0042] More preferably, in S10, the catalyst is added by dropping, and the dropping rate of the catalyst is 5 mL / min to 10 mL / min.
[0043] More preferably, in S10, the first organic solvent is acetonitrile.
[0044] More preferably, in S10, the mass-to-volume ratio of compound 1 to the first organic solvent is 1 g: 5 mL to 20 mL.
[0045] In a particularly preferred embodiment, in S10, the procedure for separating compound 2 after the reaction is completed is as follows: the second reaction solution after the reaction is completed is first neutralized to neutral with saturated sodium bicarbonate, concentrated under reduced pressure to remove the first organic solvent, filtered to obtain an aqueous solution of crude product, and the aqueous solution of crude product is purified by C-18 column chromatography to obtain compound 2. The eluent for C-18 column chromatography purification is a mixture of acetonitrile and 0.1% (wt) hydrochloric acid, and the volume percentage of acetonitrile in the eluent is 10%~30%.
[0046] At this point, since the eluent from the C-18 column chromatography purification contains 0.1% (wt) hydrochloric acid, and X is Cl, the reactant obtained in S10 is compound 2' with the following structural formula: .
[0047] X can be F, Br, or I, which can be achieved using anion exchange resins. The specific method is consistent with patent CN202511201944.X (Trigonelline metformin salt and its preparation method).
[0048] It should be noted that the reaction in S10 can be monitored by TLC.
[0049] S20. Compound 2 is dissolved in a second organic solvent, and a strongly alkaline aqueous solution is added at 0~5 °C. The resulting third reaction solution is stirred and reacted. After the reaction is completed, compound 3 is separated, which is the desired metformin derivative.
[0050] In S20, the reaction formula is as follows: .
[0051] Preferably, in S20, the strongly alkaline aqueous solution is an aqueous solution of sodium hydroxide or potassium hydroxide.
[0052] Preferably, in S20, the concentration of the strongly alkaline aqueous solution is 0.5 M to 2 M.
[0053] Preferably, in S20, during the stirring reaction of the third reaction liquid, the reaction time is 1 h to 3 h.
[0054] More preferably, in S20, the molar ratio of compound 2 to the solute in the strongly alkaline aqueous solution is 1:1.5~5.
[0055] More preferably, in S20, the second organic solvent is methanol.
[0056] More preferably, in S20, the mass-to-volume ratio of compound 2 and the second organic solvent is 1 g: 2 mL to 6 mL.
[0057] More preferably, in S20, the strongly alkaline aqueous solution is added dropwise, and the dropping rate of the strongly alkaline aqueous solution is 5 mL / min to 20 mL / min.
[0058] In a particularly preferred embodiment, in S20, the operation of separating compound 3 after the reaction is completed is as follows: after the reaction is completed, the third reaction solution is added with hydrochloric acid aqueous solution under ice bath until the pH of the system is less than 7, concentrated under reduced pressure to obtain crude product, and the crude product is purified by reversed-phase column chromatography to obtain compound 3. The eluent for reversed-phase column chromatography purification is a mixture of acetonitrile and 0.1% (wt) hydrochloric acid, and the volume percentage of acetonitrile in the eluent is 5%~20%.
[0059] At this point, because the third reaction solution was adjusted to pH with hydrochloric acid aqueous solution under ice bath conditions, and the eluent from reverse-phase column chromatography contained 0.1% (wt) hydrochloric acid, X is Cl, the reactant obtained in S20 is compound 3' with the following structural formula: .
[0060] X can be F, Br, or I, which can be achieved using anion exchange resins. The specific method is consistent with patent CN202511201944.X (Trigonelline metformin salt and its preparation method).
[0061] It should be noted that the reaction in S20 can be monitored by TLC.
[0062] The present invention also discloses an embodiment of the application of the above-mentioned metformin derivative in improving lipid metabolism in liver cells and improving adipocyte aging.
[0063] The following are specific examples.
[0064] Unless otherwise specified, the experimental methods used in the examples are conventional methods.
[0065] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.
[0066] The detection instrument model, settings, and descriptions are as follows in the following embodiments: 1) MRI: Magnetic Resonance Imaging System Model: AVANCE III 400 2) Purity test by high performance liquid chromatography (HPLC): Dissolve 20.0 mg of the test substance in 20 mL of methanol, and detect the purity of the test substance by the area method of high performance liquid chromatography (HPLC).
[0067] The HPLC conditions are as follows: Instrument model: Thermo Vanquish, featuring a quaternary pump and a variable wavelength detector (VWD). Separation column: Acclaim TM 120 C18 column, 4.6 mm x 250 mm, particle size 5 μm, pore size 120 Å Column constant temperature: 25 °C Mobile phase: 0.1% (wt) hydrochloric acid, chromatographic grade acetonitrile; gradient elution conditions are shown in Table 1. Flow rate: 1.0 mL / min Detection: VWD: 220 nm and 254 nm Retention time: 7.54 min Table 1: Elution gradient for high performance liquid chromatography 3) Mass spectrometer: Instrument Model: Thermo Scientific / Orbitrap Exploris 240 Detection range: m / z 40 to 6000 Resolution: Up to 240,000 (FWHM) at m / z 200 Quality accuracy: 1 ppm (internal standard calibration) for both Level 1 and Level 2, and 3 ppm (external standard calibration). Scanning speed: up to 22 Hz Sensitivity: For reserpine (m / z 609.2807, ESI+ ionization), signal-to-noise ratio (S / N) ≥ 5000:1 in a single Orbitrap mass analyzer scan. Precise mass number: 1 ppm RMS (after internal standard calibration) Example 1: Preparation of compound 2' First, tetraacetylribose (10.00 g, 31.42 mmol), nicotinic acid metformin (11.04 g, 47.13 mmol) and... N,O - Bis(trimethylsilyl)acetamide (38.35 g, 188.52 mmol) was dissolved in acetonitrile (100 mL) and stirred at 80 °C for 2 h. Then, trimethylsilyl trifluoromethanesulfonate (6.98 g, 31.42 mmol) was added at a dropping rate of 8 mL / min. After the addition was complete, the reaction mixture was stirred at 80 °C for 2 h. The reaction was monitored by TLC (the reaction mixture was diluted with dichloromethane and spotted onto a silica gel plate, with dichloromethane:methanol = 20:1 (v / v) as the developing solvent. After development, the sample was observed under a UV lamp at 254 nm. The R of compound 2' of the product was observed. f = 0.3).
[0068] After the reaction was completed, the reaction solution was first neutralized with saturated sodium bicarbonate aqueous solution until the system was neutral, then concentrated under reduced pressure to remove acetonitrile, and filtered to obtain an aqueous solution of the crude product. The aqueous solution of the crude product was purified by C-18 column chromatography (10%-30% acetonitrile / 0.1% (wt) hydrochloric acid, i.e., acetonitrile accounts for 10-30% of the sum of the volumes of acetonitrile and 0.1% (wt) hydrochloric acid) to obtain compound 2' (5.31 g).
[0069] The structure of compound 2' is confirmed as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.74 (s, 1H), 9.31 (d, J = 8.0 Hz, 1H), 9.27(d, J = 6.4 Hz, 1H), 8.39 (dd, J = 8.0, 6.4 Hz, 1H), 7.24 (s, 2H), 6.74 (d, J =3.6 Hz, 1H), 5.64 (dd, J = 5.5, 3.8 Hz, 1H), 5.43 (dd, J = 11.8, 6.2 Hz, 1H), 4.76 (dd, J = 8.7, 3.8 Hz, 1H), 4.50 (dd, J = 12.7, 4.1 Hz, 1H), 4.44 (dd, J =12.7, 2.9 Hz, 1H), 3.24 (s, 3H), 3.13 (s, 3H), 2.16 (s, 3H), 2.11 (s, 3H), 2.01 (s, 3H), the spectrum is as follows. Figure 2 As shown.
[0070] 13 C NMR (101 MHz, DMSO- d 6) δ 170.5, 170.0, 169.7, 166.7, 165.0, 145.8, 143.1, 140.9, 137.3, 128.8, 97.4, 82.8, 76.1, 69.6, 62.9, 36.3, 20.9, 20.9, 20.8, the spectrum is as follows Figure 3 As shown.
[0071] Example 2: Preparation of compound 3' Compound 2' (10.00 g, 18.91 mmol) was dissolved in methanol (30 mL), and 28.36 mL of 1M sodium hydroxide aqueous solution was added in an ice bath at a dropping rate of 15 mL / min. After the addition was complete, the mixture was stirred in an ice bath for 3 h. The reaction progress was monitored by HPLC until the starting material was basically consumed.
[0072] After the reaction was complete, 1M hydrochloric acid aqueous solution was added to the reaction solution under ice bath until the pH of the system was less than 7, and the solution was concentrated under reduced pressure to obtain the crude product. The crude product was purified by reversed-phase column chromatography (5%-20% acetonitrile / 0.1% (wt) hydrochloric acid, i.e., acetonitrile accounts for 5%-20% of the sum of the volumes of acetonitrile and 0.1% (wt) hydrochloric acid) to obtain the product compound 3', namely NAR metformin (1.32 g), with a purity of 95.244%. See details. Figure 4 .
[0073] The structure of compound 3' is confirmed as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.92 (s, 1H), 9.32 (d, J = 6.2 Hz, 1H), 9.28 (d, J = 8.0 Hz, 1H), 8.33 (dd, J = 8.0, 6.2 Hz, 1H), 7.03-7.39 (m, 2H), 6.23(d, J = 4.9 Hz, 1H), 4.37 – 4.21 (m, 2H), 4.19 – 4.12 (m, 1H), 3.83 (dd, J =12.2, 3.0 Hz, 1H), 3.74 (dd, J = 12.2, 2.6 Hz, 1H), 3.25 (s, 3H), 3.12 (s, 3H), the spectrum is as follows Figure 5 As shown.
[0074] 13 C NMR (101 MHz, DMSO- d 6) δ 167.1, 165.4, 165.2, 145.2, 142.8, 140.8, 137.4, 128.4, 100.6, 88.9, 78.5, 70.8, 60.9, 36.4, 36.2, the spectrum is as follows Figure 6 As shown.
[0075] HRMS (ESI)m / z: [M] + calcd for C 15 H 21 N6O4 + : 349.1619, found :349.1591, spectrum as follows Figure 7 As shown.
[0076] Example 3: Preparation of compound 3' First, tetraacetylribose (15.00 g, 47.13 mmol), nicotinic acid metformin (11.04 g, 47.13 mmol), and... N,O Bis(trimethylsilyl)acetamide (57.52 g, 282.78 mmol) was dissolved in acetonitrile (300 mL) and stirred at 80 °C for 2 h. Then, trimethylsilyl trifluoromethanesulfonate (20.94 g, 94.26 mmol) was added at a dropping rate of 5 mL / min. After the addition was complete, the reaction mixture was stirred at 60 °C for 8 h. The reaction was monitored by TLC (the reaction mixture was diluted with dichloromethane and spotted onto a silica gel plate, with dichloromethane:methanol = 20:1 (v / v) as the developing solvent. After development, the sample was observed under a UV lamp at 254 nm. The R of compound 2' of the product was observed. f = 0.3).
[0077] After the reaction was completed, the reaction solution was first neutralized with saturated sodium bicarbonate aqueous solution until the system was neutral, then concentrated under reduced pressure to remove acetonitrile, and filtered to obtain an aqueous solution of the crude product. The aqueous solution of the crude product was purified by C-18 column chromatography (gradient elution, 10%-30% acetonitrile / 0.1% (wt) hydrochloric acid, i.e., acetonitrile accounts for 10-30% of the sum of the volumes of acetonitrile and 0.1% (wt) hydrochloric acid) to obtain compound 2' (8.42 g).
[0078] Compound 2' (4.00 g, 7.56 mmol) was dissolved in methanol (8 mL), and 37.81 mL of 1M potassium hydroxide aqueous solution was added in an ice bath at a dropping rate of 20 mL / min. After the addition was complete, the mixture was stirred at 5 °C for 1 h. The reaction progress was monitored by HPLC until the starting material was basically consumed.
[0079] After the reaction was completed, 1M hydrochloric acid aqueous solution was added to the reaction solution under ice bath until the pH of the system was less than 7, and the crude product was obtained by concentration under reduced pressure. The crude product was purified by reversed-phase column chromatography (5%-20% acetonitrile / 0.1% (wt) hydrochloric acid, i.e., acetonitrile accounts for 5%-20% of the sum of the volumes of acetonitrile and 0.1% (wt) hydrochloric acid) to obtain product compound 3', namely NAR metformin (0.7 g).
[0080] Example 4: Preparation of compound 3' First, tetraacetylribose (5.00 g, 15.71 mmol), nicotinic acid metformin (11.04 g, 47.13 mmol) and... N,O Bis(trimethylsilyl)acetamide (76.69 g, 377.04 mmol) was dissolved in acetonitrile (25 mL) and stirred at 80 °C for 2 h. Then, trimethylsilyl trifluoromethanesulfonate (10.47 g, 47.13 mmol) was added at a dropping rate of 10 mL / min. After the addition was complete, the reaction mixture was stirred at 70 °C for 4 h. The reaction was monitored by TLC (the reaction mixture was diluted with dichloromethane and spotted onto a silica gel plate, with dichloromethane:methanol = 20:1 (v / v) as the developing solvent. After development, the sample was observed under a UV lamp at 254 nm. The R of compound 2' of the product was observed. f = 0.3).
[0081] After the reaction was completed, the reaction solution was first neutralized with a saturated sodium bicarbonate aqueous solution until the system was neutral, then concentrated under reduced pressure to remove acetonitrile, and filtered to obtain an aqueous solution of the crude product. The aqueous solution of the crude product was purified by C-18 column chromatography (10%-30% acetonitrile / 0.1% (wt) hydrochloric acid, i.e., acetonitrile accounts for 10-30% of the sum of the volumes of acetonitrile and 0.1% (wt) hydrochloric acid) to obtain compound 2' (5.67 g).
[0082] Compound 2' (5.00 g, 9.45 mmol) was dissolved in methanol (30 mL), and 18.91 mL of 1M sodium hydroxide aqueous solution was added in an ice bath at a dropping rate of 5 mL / min. After the addition was complete, the mixture was stirred at 3 °C for 2 h. The reaction progress was monitored by HPLC until the starting material was basically consumed.
[0083] After the reaction was completed, 1M hydrochloric acid aqueous solution was added to the reaction solution under ice bath until the pH of the system was less than 7, and the crude product was concentrated under reduced pressure. The crude product was purified by reversed-phase column chromatography (5%-20% acetonitrile / 0.1% (wt) hydrochloric acid, i.e., acetonitrile accounts for 5%-20% of the sum of the volumes of acetonitrile and 0.1% (wt) hydrochloric acid) to obtain product compound 3', namely NAR metformin (1.23 g).
[0084] Example 5: Accelerated Stability Test The NAR metformin samples (3 small samples, 50.0 mg each) prepared in Example 2 were placed in black sealed bags and placed in an accelerated chamber at 37 °C and 75% humidity. Accelerated stability tests were conducted on the 3 small samples for 1 month, 2 months and 3 months respectively. After the expiration, 20.0 mg of each small sample was weighed and the sample content was detected by the same HPLC method as above.
[0085] The retention rate of the sample = the sample content detected by HPLC after a specific time period / the initial sample content. The initial sample content is considered to be 100%. The retention rates of the corresponding samples are shown in Table 2.
[0086] After three months of accelerated testing, the retention rate decreased slightly, but remained above 90%, meeting the general product qualification standards for accelerated testing.
[0087] Table 2: Retention rate of samples at different retention times Example 6: Experiment on the Improvement of Senescence in 3T3-L1 Cells 3T3-L1 cells (Pronosai, product model CL-0006) were seeded in 96-well cell culture plates, with 100 µL of 2000 cells per well. The 3T3-L1 preadipocytes were induced to differentiate into mature adipocytes using DMEM medium containing 10 µg / mL insulin, 0.5 µM 3-isobutyl-1-methylxanthine, 10 µM indoleacetic acid, 1 µM dexamethasone, and 1 µM rosiglitazone. A cell senescence model was then established by treatment with 0.2 μM doxorubicin ADR for 24 h. Different drug interventions were then applied, all at a concentration of 10 µM. Samples were collected after overnight culture.
[0088] The experimental groups are as follows: Sham group: Wild-type cells without any treatment; Veh group: 3T3-L1 adipocytes were induced with ADR without any other drug treatment; Metf group: Intervention with ADR and 10 μM metformin; NAR-Metf: NAR metformin intervention prepared using ADR and 10 μM in Example 2; Following drug intervention, cellular senescence was utilized. β - Use the galactosidase staining kit (Beyotime, C0602) for staining. The specific procedure is as follows: aspirate the cell culture medium from the six-well plate, wash once with PBS, and add 1 mL of PBS. β - Fix with galactosidase staining fixative at room temperature for 15 min. Aspirate the cell fixative and wash the cells three times with PBS for 3 min each time. Aspirate the PBS buffer and add 1 mL of staining working solution to each well. Incubate overnight at 37 ℃. Finally, observe under a regular light microscope. The results are as follows: Figure 8 As shown. The observations were counted and statistically analyzed, and the results are as follows. Figure 9 As shown.
[0089] from Figure 8 and Figure 9As can be seen, compared with the Sham group (blank group), the model group (Veh) showed improved cell senescence after ADR-induced cell senescence. β - The area of galactosidase-positive cells increased significantly. After intervention with metformin (Metf group) and NAR metformin (NAR-Metf group)... β The area of positive galactosidase was significantly reduced, indicating that NAR metformin can achieve the same level of improvement in cell senescence in the model group as metformin.
[0090] Example 7: HepG2 cell line experiment HepG2 cells (Pronosai, product model CL-0103) were seeded in 96-well cell culture plates, with 100 µL of 2000 cells per well. A cell model was induced using oleic acid (OA), and different drugs were used for intervention, all at a concentration of 10 µM. After overnight culture, samples were collected, and indicators of triglycerides and lipid accumulation were measured.
[0091] (1) Effects of different drug administration groups on the improvement of triglyceride levels The experimental groups are as follows: Sham group: Wild-type cells without any treatment; Veh group: HepG2 cells were treated with OA to induce lipid deposition, without any other drug treatment; Metf group: HepG2 lipid deposition induced by OA was followed by treatment with 10 μM metformin; NAR-Metf group: treated with 10 μM NAR metformin prepared in Example 2 after OA-induced HepG2 lipid deposition; After obtaining the samples, cells were extracted with isopropanol, and lipase was added. The mixture was then incubated at 37 °C for 20 min to hydrolyze triglycerides into glycerol and fatty acids. Triglyceride detection working solution (Beyotime, S0219M) was then added, and the mixture was incubated at 37 °C in the dark for 60 min. The absorbance at 570 nm was measured using a microplate reader. The results are as follows: Figure 10 As shown.
[0092] from Figure 10 As can be seen, compared with the Sham group (blank group), the model group (Veh) showed a significant increase in triglyceride levels after OA induction. Both metformin (Metf group) and NAR metformin (NAR-Metf group) interventions reduced triglyceride levels, with the NAR metformin (NAR-Metf group) showing the most significant reduction (P<0.05), indicating the best effect.
[0093] (2) Induction of lipid deposition in HepG2 cells using oleic acid (OA) The experimental groups are as follows: Sham group: Wild-type cells without any treatment; Veh group: HepG2 cells were treated with OA to induce lipid deposition, without any other drug treatment; Metf group: HepG2 lipid deposition induced by OA was followed by treatment with 10 μM metformin; NAR-Metf group: HepG2 lipid deposition induced by OA was followed by treatment with 10 μM NAR metformin; After obtaining the samples, cells were fixed with 4% paraformaldehyde for 10 min, washed once with PBS, stained with Oil Red O (Sigma-Aldrich, O0625) at a constant temperature in the dark for 10-30 min, the staining solution was discarded, and the cells were washed twice with PBS. Images were taken under a light microscope, and the results are as follows. Figure 11 As shown in the figure. Then, 60% volume of isopropanol and 40% volume of 75% ethanol were mixed to elute Oil Red, and its OD value was measured at 510 nm using a microplate reader. The results are shown in the figure. Figure 12 As shown.
[0094] from Figure 11 and Figure 12 As can be seen, compared with the Sham group (blank group), the model group (Veh) showed significant lipid deposition, with lipid droplets significantly enlarged and aggregated. Treatment with metformin (Metf group) and NAR metformin (NAR-Metf group) reduced lipid droplet size, with the NAR metformin (NAR-Metf group) showing a greater improvement in lipid deposition (P<0.05), indicating that NAR metformin has an effect on improving lipid metabolism in liver cells.
[0095] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.
[0096] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A metformin derivative, characterized in that, The metformin derivative is compound 3 having the following structural formula: ; Where X is F, Cl, Br or I.
2. A method for preparing the metformin derivative according to claim 1, characterized in that, Includes the following steps: Step 1: Compound 1, nicotinic acid metformin, and a protecting agent are dissolved in a first organic solvent. The resulting first reaction solution is stirred at 60 ℃~80 ℃. After the reaction is complete, a catalyst is added, and the resulting second reaction solution is stirred at 60 ℃~80 ℃. After the reaction is complete, compound 2 is separated. The reaction formula is as follows: , Where X is F, Cl, Br or I; Step 2: Dissolve compound 2 in a second organic solvent, add a strongly alkaline aqueous solution at 0-5 °C, and stir the resulting third reaction solution. After the reaction is complete, separate to obtain compound 3, which is the desired metformin derivative. The reaction formula is as follows: 。 3. The method for preparing the metformin derivative according to claim 2, characterized in that, In step one, the molar ratio of nicotinic acid metformin to compound 1 is 1~3:1, the molar ratio of the protective agent to nicotinic acid metformin is 4~8:1, and the molar ratio of the catalyst to compound 1 is 1~3:
1.
4. The method for preparing the metformin derivative according to claim 3, characterized in that, The catalyst is trimethylsilyl trifluoromethanesulfonate; The protective agent is N,O -Bis(trimethylsilyl)acetamide; The catalyst is added by dropping, and the dropping rate is 5 mL / min to 10 mL / min.
5. The method for preparing the metformin derivative according to claim 2, characterized in that, The first organic solvent is acetonitrile; The mass-to-volume ratio of compound 1 to the first organic solvent is 1 g: 5 mL to 20 mL.
6. The method for preparing the metformin derivative according to claim 2, characterized in that, In step one, the operation of separating compound 2 after the reaction is completed is as follows: the second reaction solution after the reaction is completed is first neutralized to neutral with saturated sodium bicarbonate, concentrated under reduced pressure to remove the first organic solvent, filtered to obtain an aqueous solution of crude product, and the aqueous solution of crude product is purified by C-18 column chromatography to obtain compound 2. The eluent for the C-18 column chromatography purification is a mixture of acetonitrile and 0.1 wt% hydrochloric acid, and the volume percentage of acetonitrile in the eluent is 10%~30%.
7. The method for preparing the metformin derivative according to any one of claims 2 to 6, characterized in that, In step two, the strongly alkaline aqueous solution is an aqueous solution of sodium hydroxide or potassium hydroxide. The concentration of the strongly alkaline aqueous solution is 0.5 M to 2 M; The molar ratio of the solute in compound 2 to the strongly alkaline aqueous solution is 1:1.5~5.
8. The method for preparing the metformin derivative according to claim 7, characterized in that, The second organic solvent is methanol; The mass-to-volume ratio of compound 2 to the second organic solvent is 1 g : 2 mL to 6 mL; The strongly alkaline aqueous solution is added dropwise at a rate of 5 mL / min to 20 mL / min.
9. The method for preparing the metformin derivative according to claim 7, characterized in that, In step two, the operation of separating compound 3 after the reaction is completed is as follows: after the reaction is completed, the third reaction solution is added with hydrochloric acid aqueous solution under ice bath until the pH of the system is less than 7, and concentrated under reduced pressure to obtain crude product. The crude product is purified by reversed-phase column chromatography to obtain compound 3. The eluent of the reversed-phase column chromatography purification is a mixture of acetonitrile and 0.1% wt hydrochloric acid, and the volume percentage of acetonitrile in the eluent is 5%~20%.
10. The use of the metformin derivative of claim 1 in improving lipid metabolism in liver cells and improving adipocyte senescence.
Citation Information
Patent Citations
Trigonelline metformin salt and preparation method thereof
CN121318832A
Crystal form of nicotinoyl metformin and preparation method thereof
CN121494781A
